ClinicalTrials.gg
RecruitingNCT06585228MtH-DETECTUpdated Feb 3, 2025

Detecting Cardiac Thrombi in Acute Ischemic Stroke on Cardiac CT Versus Transoesophageal Echocardiography

An observational study in Ischemic Stroke, Cardioembolic Stroke and Thrombus; Embolism, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Primary conditionEmbolic StrokeRegistry: Ischemic StrokeReclassifiedWhy we changed it
Registry
Ischemic Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Embolic Stroke
Why
  1. The study's listed conditions name Embolic Stroke, a narrower term within Ischemic Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
39
Ages
18 Years and older
Sex
All
01

Study summary

Rationale:

Cardiac CT acquired during the acute stroke imaging protocol (acute cardiac CT) has recently been shown to have a superior diagnostic yield than transthoracic echocardiography, which is currently the most commonly used method to screen for structural sources of cardioembolism in patients with acute ischemic stroke. The most common finding on acute cardiac CT are cardiac thrombi located in the left atrium (LA) and specifically the left atrial appendage (LAA). The higher diagnostic yield of acute cardiac CT compared to TTE is partially explained because CT allows for better visualization of the LAA, but also because cardiac thrombi may dissolve in the first days after stroke. Whether acute cardiac CT is the optimal diagnostic modality for LA thrombi in stroke patients is unknown, since data comparing it to transoesophageal echocardiography (TEE), which is the reference standard to detect LA thrombi, are lacking. The general hypothesis of this study is that acute cardiac CT is the optimal method to detect LA thrombi in ischemic stroke patients, since TEE can miss LA thrombi that dissolve in the first days after stroke.

Objectives:

  1. Determine whether acute cardiac CT has a higher diagnostic probability of detecting LA thrombi compared to TEE or repeated cardiac CT in the subacute phase of ischemic stroke by assessing the rate at which LA thrombi dissolve in the first days after ischemic stroke occurrence.
  2. Determine the positive predictive value of acute cardiac CT compared to TEE for the detection of LA thrombi. Study design: Prospective, single-centre, observational cohort Study population: 39 patients of 18 years or older with acute ischemic stroke and a LA thrombus detected on cardiac CT acquired during the acute stroke imaging.

Main study parameters/endpoints:

  1. Rate at which LA thrombi visualized on acute cardiac CT dissolve in the first days after ischemic stroke.
  2. False-positive rate for detection of left atrial thrombi on acute cardiac CT compared to TEE. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Clinical and imaging patient data which are obtained as part of standard care will be prospectively collected after written informed consent. Patient with a LA thrombus on acute cardiac CT will undergo TEE for research purposes after obtaining written informed consent. TEE is semi-invasive and associated with a small risk of major complications (\<0.2%). Patients will also be exposed to additional radiation (1.4 mSV) due to sequential cardiac CT after TEE. The Radiation Dose Committee deemed this to be an intermediate risk. In a small minority of patients (\<10%), another cardiac CT will be acquired 2 minutes after this sequential cardiac CT to ensure a clear, final assessment of the presence of an atrial appendage thrombus. This will result in a total additional radiation of 3 mSV for the two additional cardiac CT's. The Radiation Dose Committee deemed this to be an intermediate risk. As part of standard care, patients will be contacted for follow-up evaluation by a trained stroke nurse at 90 days. As a result of ischemic stroke, some patients become incapacitated to an extent they are unable to give informed consent. In these cases, the legal representative will be asked for informed consent. Decreased leveI of consciousness or aphasia are typical clinical characteristics of cardioembolic stroke. Therefore, it is pivotal to also include incapacitated acute ischemic stroke patients. Excluding these patients from the study would render the study non-representative of the study's target population (acute ischemic stroke patients with cardioembolic stroke due to LA thrombus).
02

Conditions studied

  • Ischemic Stroke
  • Cardioembolic Stroke
  • Thrombus; Embolism
  • Left Atrial Thrombosis
  • Left Atrial Appendage Thrombosis

Browse trials for

Keywords

  • Cardiac CT
  • Transoesophageal echocardiography
  • Ischemic stroke
03

In context

Embolic Stroke Reclassified

40 studies on the registry are indexed under Embolic Stroke; 11 are open to participants now.

This study's planned enrollment of 39 is below the median of 364 across 27 observational studies indexed under Embolic Stroke.

Browse Embolic Stroke studies →

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 183 are open to participants now.

Compared within Embolic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ischemic Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 18 years or older with acute ischemic stroke and a LA thrombus detected on cardiac CT acquired during the initial stroke imaging protocol at Amsterdam UMC, location AMC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Clinical diagnosis of acute ischemic stroke
  • Written from patient or representative
  • Radiological diagnosis of cardiac thrombus in the LA, including the LAA, on cardiac CT acquired during the initial stroke imaging protocol.

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis other than acute ischemic stroke, such as: , intracerebral haemorrhage, subarachnoid haemorrhage, epilepsy, tumor.
  • Absolute for TEE:

    • Perforated viscus
    • Esophageal stricture
    • Esophageal tumor
    • Esophageal perforation, laceration
    • Esophageal diverticulum
    • Active upper GI bleed
  • Absolute contraindication for repeat cardiac CT

    • Documented previous severe reaction to iodinated contrast media, including anaphylaxis, angioedema and bronchospasm.
    • Severely impaired kidney function defined as estimated of 30 mL/min/1.73 m2.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
39 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testCardiac Computed Tomography

    Cardiac CT acquired during the acute stroke imaging protocol

    Also known as: Cardiac CT, CCT

  • Diagnostic testTransesophageal echocardiography

    Ultrasound through the oesophagus to assess cardiac structures.

    Also known as: TEE

  • Diagnostic testRepeated Cardiac Computed Tomography

    A second cardiac CT performed after the TEE.

    Also known as: Cardiac CT

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a left atrial thrombus

    The proportion of patients with a LA thrombus detected on acute cardiac CT that dissolves in the first days after stroke, defined as thrombi that are seen on initial cardiac CT but are no longer visible on TEE and repeated cardiac CT.

    Time frame: The assessment of a left atrial thrombus is performed when the patient arrives at the Emergency Department and undergoes the acute stroke imaging protocol including a cardiac CT.

  2. Positive predictive value of acute cardiac CT compared to TEE.

    Positive predictive value of acute cardiac CT compared to TEE.

    Time frame: The assessment of a left atrial thrombus is performed when the patient arrives at the Emergency Department and undergoes the acute stroke imaging protocol including a cardiac CT. The TEE is performed <7 days after the cardiac CT.

Secondary outcomes

  1. Other pre-defined high-risk and non-high-risk sources of embolism on cardiac CT and TEE

    Other high-risk and non-high-risk sources that have been detected on cardiac CT and TEE.

    Time frame: Cardiac CT is performed and assessed when the patients arrives at the Emergency Department. The TEE is performed <7 days after the cardiac CT.

  2. Clinical impact of cardiac thrombi

    The clinical impact of detecting cardiac thrombi and other sources of embolism on acute cardiac CT and TEE, including any impact on stroke etiology according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria

    Time frame: The clinical data of patients with a thrombi is collected on arrival at the Emergency Department and follow-up is performed at 90 days and 2 years to assess functional outcome, recurrent stroke and cardiovascular events

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jul 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 5, 2024
StartActual
Aug 19, 2024
Primary completionEst.
Jul 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06585228
Responsible party
Jonathan Coutinho (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Sep 5, 2024
Start date
Aug 19, 2024
Primary completion
Jul 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Feb 3, 2025

Study contacts

Shan Sui Nio, MD
Contact
s.nio@amsterdamumc.nl
020 5664591 ext. 0031
Jonathan M Coutinho, MD, PhD
Contact
j.coutinho@amsterdamumc.nl
0205662004 ext. 0031
Jonathan M Coutinho, MD, PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion